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Abstract
Background: Immigrants to the U.S. are required to undergo overseas screening for tuberculosis (TB),
but the value of evaluation and treatment following entry to the U.S. is not well understood. We
determined the cost-effectiveness of domestic follow-up of immigrants identified as tuberculosis suspects
through overseas screening.
Methods: Using a stochastic simulation for tuberculosis reactivation, transmission, and follow-up for a
hypothetical cohort of 1000 individuals, we calculated the incremental cost-effectiveness of follow-up and
evaluation interventions. We utilized published literature, California Reports of Verified Cases of
Tuberculosis (RVCTs), demographic estimates from the California Department of Finance, Medicare
reimbursement, and Medi-Cal reimbursement rates. Our target population was legal immigrants to the
United States, our time horizon is twenty years, and our perspective was that of all domestic health-care
payers. We examined the intervention to offer latent tuberculosis therapy to infected individuals, to
increase the yield of domestic evaluation, and to increase the starting and completion rates of LTBI therapy
with INH (isoniazid). Our outcome measures were the number of cases averted, the number of deaths
averted, the incremental dollar cost (year 2004), and the number of quality-adjusted life-years saved.
Results: Domestic follow-up of B-notification patients, including LTBI treatment for latently infected
individuals, is highly cost-effective, and at times, cost-saving. B-notification follow-up in California would
reduce the number of new tuberculosis cases by about 6–26 per year (out of a total of approximately
3000). Sensitivity analysis revealed that domestic follow-up remains cost-effective when the hepatitis rates
due to INH therapy are over fifteen times our best estimates, when at least 0.4 percent of patients have
active disease and when hospitalization of cases detected through domestic follow-up is no less likely than
hospitalization of passively detected cases.
Conclusion: While the current immigration screening program is unlikely to result in a large change in
case rates, domestic follow-up of B-notification patients, including LTBI treatment, is highly cost-effective.
If as many as three percent of screened individuals have active TB, and early detection reduces the rate of
hospitalization, net savings may be expected.
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Background
The global tuberculosis (TB) epidemic strongly influences
the incidence of TB within California, as evidenced by the
occurrence of 75 percent of California TB cases in 2002 in
persons born outside the U.S. [1]. Screening of foreign-
born persons is often recommended [2] to detect active TB
at an earlier stage. Such screening and evaluation may also
identify individuals with latent TB infection (LTBI), for
whom therapy could prevent future disease [3].
Federal law requires immigrants to the U.S. to undergo an
overseas examination for TB (and other conditions) [4].
Individuals are screened with chest radiographs (and spu-
tum smears for acid fast bacteria, if indicated) to identify
potentially infectious individuals who are barred from
entry into the U.S. Those with active TB who are sputum
smear-negative, or who have inactive TB, receive a B-noti-
fication; such individuals are instructed to report to a local
health jurisdiction within 30 days after entry. In Califor-
nia (1992 to 1996), three and one half percent of such
persons with a B-notification were reported to have active
TB within one year of arrival [5]. Upon domestic evalua-
tion, individuals without active disease may fall into one
of three categories (using the American Thoracic Society
classes [6]): TB0 (no evidence of infection), TB2 (evidence
of infection, but no evidence of disease), or TB4 (stable
radiographic abnormalities suggestive of TB together with
evidence of TB infection, and negative bacteriologic stud-
ies) [7]. Individuals in classes TB2 and TB4 are eligible for
LTBI therapy, unless already treated. Studies of domestic
follow-up have found that compared to recently-arrived
TB cases in California without B-notification, those with a
B-notification were reported with TB sooner after their
arrival in the U.S. [5], suggesting that domestic follow-up
of B-notification patients is detecting cases sooner than
they would have been detected passively. Cases with a B-
notification were less likely to have smear-positive pulmo-
nary disease (unsurprisingly, since smear-positive individ-
uals are not assigned to class B and cannot legally enter
the U.S. until treatment has resulted in smear conversion);
nevertheless, some B-notification patients have smear-
positive disease upon domestic follow-up.
Is domestic follow-up by local health jurisdictions of
patients identified as suspected cases overseas a good pub-
lic health investment, and if so, how should those
resources be most efficiently invested? To date, the only
U.S. cost-effectiveness study focused on the savings that
result from excluding cases from entry into the U.S., not
on the yield of domestic follow-up [8]. In this report, we
examine the cost-effectiveness [9-15] of the domestic fol-
low-up of B-notification patients by determining the
number of TB cases prevented, the number of deaths
among persons with TB averted, and the number of qual-
ity-adjusted life-years (QALYs) saved, for each dollar
invested. We first consider only the costs and benefits
resulting from domestic evaluation and active case-find-
ing, i.e., the earlier detection of cases of active TB disease.
We then determine the additional costs and additional
benefits of therapy of latent TB infection (LTBI) for suita-
ble persons identified by domestic evaluation. Finally, we
determine the most cost-effective means to improve the
yield of the program.
Methods
Overview
We determined how domestic B-notification follow-up
would change the expected dollar cost, the number of
incident cases of TB, the number of deaths among individ-
uals with TB, and the number of QALYs lost, by simulat-
ing the natural history of a hypothetical cohort of 1000 B-
notification patients and their infected contacts for 20
years after entry (Figure 1). Individuals at the baseline
may have active disease, may be latently infected (and
possibly develop active disease during the 20-year analytic
horizon), or may even be uninfected (because radiologic
screening is not highly specific [4,7]). Individuals with
active TB may infect new individuals, who are then added
to the simulated cohort. Domestic B-notification fol-
lowup would detect individuals at the baseline who have
active disease, and such earlier detection would reduce
costs and transmission [16-18]. Screening for active dis-
ease also identifies individuals in class TB2 or TB4; addi-
tional resources spent on their LTBI therapy reduce future
TB [19], but may cause hepatitis in some individuals [20].
We neglect the incidence of infection among those unin-
fected at baseline (because this is unrelated to B-notifica-
tion follow-up), although some uninfected individuals
will be misclassified as being latently infected (and thus
incur costs and some adverse health outcomes). We used
an individual-based stochastic simulation (for example,
see [21]) based on a natural history model of tuberculosis,
e.g. [22-26]. Because the model structure reflected individ-
ual variability in TB progression, for each scenario we
averaged the results of 10 000 replications of the model to
determine the model outputs we report.
Perspective
We adhered to the reference case scenario recommended
by the Panel on Cost-effectiveness in Health and Medicine
[27], except that (1) we took a domestic all-payers per-
spective rather than a societal perspective (we excluded
indirect costs of lost productivity, lost wages, and time
spent seeking health care), and (2) we excluded the costs
of the overseas screening examination, as well as the ben-
efits of overseas treatment of the smear-positive cases dis-
covered before immigration.
We chose this perspective to provide guidance to local
health jurisdictions who may need to decide how much toBMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
Page 3 of 15
(page number not for citation purposes)
invest in follow-up of new immigrants with tuberculosis
B-notifications. Given that overseas screening is currently
mandated for new immigrants to the United States and
that the expense of such screening is already being
incurred, what benefits may be gained through appropri-
ate follow-up domestically? Or equivalently, what oppor-
tunities are missed should we fail to follow-up on those
patients who have already been identified?
All costs and health effects were discounted at three per-
cent per year.
Cohort at baseline
The age-distribution was determined from B-notifications
in the period 2001 to 2003 reported in California. We
conservatively assumed that zero to seven percent of the
cohort at the beginning of the study period (i.e., at base-
line) have active TB (conservatively assuming only seven
and one half percent of these to be smear-positive). One
study reported three and one half percent of B-notifica-
tion immigrants were reported to have active TB within
one year after arrival in the U.S., but 13 percent were
smear positive [5], though higher rates of active disease
have been found in studies where more refugees were
present [7,28]. We also assumed that 11 percent are in
class TB2, and 36 percent are persons in class TB4 who are
eligible for LTBI therapy. The remainder are assumed to
require no therapy (because they are either uninfected, or
they are former active cases of TB who received adequate
therapy for their TB disease). These proportions were
derived from unpublished local California health depart-
ment data, B-notification surveillance forms provided to
the State of California by local health jurisdictions, and
the literature [7].
LTBI therapy
According to American Thoracic Society guidelines [29],
we assume that all B-notification patients in class TB2,
regardless of age, are candidates for therapy to prevent
progression to active TB disease, because LTBI is not
detected or treated in the major countries of origin. We
assumed that providers prescribed nine months of isoni-
azid (INH), and that a complete course has a 70 percent
efficacy rate in preventing progression to active TB disease
[19]; we also assumed that some individuals would fail to
complete 9 months of therapy, but would receive some
benefit from partial completion (see Appendix [Addi-
tional file 1] for details).
We used estimates from the literature for the frequency of
INH-induced hepatitis, both fatal and non-fatal, as well as
the probability of non-hepatitis side effects [20,30-34].
We assume that costs of nonfatal hepatitis include three
additional physician visits and three sets of liver function
B-notification cohort Figure 1
B-notification cohort. A B-notification cohort in the absence of treatment is followed for twenty years. Uninfected individu-
als are symbolized by white circles, latently infected individuals (TB2 and TB4) by gray circles, and cases of active disease by 
black circles. Vertical lines symbolize transmission of Mycobacterium tuberculosis.
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tests. For ten percent of hepatitis patients requiring hospi-
talization, we assumed a seven day hospitalization [35].
Non-hepatitis side effects were assumed to require one
additional outpatient MD visit.
Natural history
Individuals with latent infection were assumed to develop
TB according to a declining function as described in other
models [9,10,36,37]; we assumed a given declining risk
for all TB2 patients, and a higher risk for TB4s. Newly
infected individuals are assumed to be at higher risk of
disease for two years, after which time they are assumed to
be equivalent to other TB2s. Our choice of declining expo-
nential risk was based on results from a cohort of recent
immigrants from Southeast Asia to Australia; this cohort
may have included recently exposed individuals at higher
risk for progression (which would have increased the aver-
age risk of the cohort), but individuals with abnormal
chest X-ray were specifically excluded [38-40].
While, as discussed before, we assumed that most individ-
uals with B-notification that have active disease upon
entry to the U.S. are found to be smear-negative, we
assume that some fraction of smear-negative individuals
will progress to smear-positive if mortality or diagnosis
does not occur. Smear-positive cases are assumed to have
higher hospitalization costs and to be more contagious
[16,17]. We also assumed that actively detected cases have
lowered hospitalization rates, even controlling for spu-
tum smear status [16,17]. Finally, we calculate race- and
age-specific TB mortality rates using Report of Verified
Case of Tuberculosis forms (RVCTs) submitted by Califor-
nia local health departments from 1996 to 2000, the most
recent years with complete outcomes.
Our model also includes some risk of transmission from
within the cohort, and the resulting higher risk of progres-
sion among those newly infected individuals. We assume
that each smear-positive case may produce new infections
over time at a rate of from 3 to 13 per year [41]; please see
the Appendix for complete details ([see Additional file
1]).
Program performance
Program performance is the local health department's
ability to maintain patient participation, i.e., to minimize
attrition as the patient presents for and completes the
evaluation, starts LTBI therapy, and completes LTBI ther-
apy. We assumed a range of attrition rates for the cohort
based on unpublished B-notification follow-up rates in
California local health departments and the literature (see
Appendix [Additional file 1] for details).
Costs were varied according to the increase in units of
medical services (for example, tuberculin skin tests and
chest radiographs) needed to serve the larger number of
clients retained. We assumed that improvements in the
fraction evaluated could be achieved by letters, phone
calls, or home visits [42], and that improvements in the
fraction completing LTBI therapy couldbe achieved by
placing some individuals on directly observed preventive
therapy [43].
Health state utilities
Health state utilities as found in the literature [9,44-48]
were used to calculate the QALYs gained and lost through
the therapy for LTBI and treatment of active TB disease. In
the absence of final results from ongoing studies that have
demonstrated the feasibility of determining health-state
utilities for tuberculosis patients [49,50], we used the best
estimates available from the literature and from previous
cost-effectiveness analyses. The mean duration patients
experienced the different health states were determined
using California-specific data and the assumption that
providers were following ATS guidelines.
Specifically, we assumed that the total lost QALYs for fatal
tuberculosis during hospitalization was 0.043, for nonfa-
tal tuberculosis during hospitalization was 0.021, and for
outpatient tuberculosis was 0.05. We assumed that the
health state utility for side effects of INH sufficient to war-
rant discontinuation (other than hepatitis) was 0.9, for
outpatient INH hepatitis was 0.735, for hepatitis under
hospitalization was 0.12, and for tuberculosis prior to
treatment was 0.9. For the base case, we assumed no disu-
tility for INH pill-taking in the absence of side-effects suf-
ficient to warrant discontinuation. The rationale for these
choices, and the uncertainty analytic ranges, are discussed
further in the Appendix [see Additional file 1].
Costs
Selected costs were estimated using a variety of sources.
We assumed a standard set of medical services for diagno-
sis and treatment; these costs are summarized in Table 1.
Medical costs were adjusted to 2004 using the Medical
Care component of the Consumer Price Index. We used
Medicare physician fee schedules where-ever possible
(using a weighted average over the nine Medicare geo-
graphic pricing regions in California based on the number
of tuberculosis cases seen in that region of California in
2004).
Otherwise, we used average nationwide allowed charges
(Medicare Part B) [51]; average nationwide figures, how-
ever, may underestimate California costs to some extent.
Where Medicare Part B charges were not available, we
used current Medi-Cal reimbursement rates (for the cost
of DOT visits and nurse prescription refill visits; see
Appendix [Additional file 1] for further discussion). Table
1 excludes costs of MDR-TB (since INH preventive therapyBMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
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cannot prevent it, such cases would occur with or without
the program), as well as HIV/TB coinfection (since indi-
viduals with HIV infection are currently excluded from
legal immigration, and we assume the risk of infection
between the overseas examination and immigration is
small).
Little information is available to determine the cost of
nurse symptom review or prescription refill visits; current
Medi-Cal reimbursement rates are approximately in
agreement with one-half hour of staff RN time (using a
recent salary survey [52]). By contrast, our use of Medi-Cal
reimbursement rates to estimate DOT costs may be con-
servative, underestimating the true costs; for instance, the
inflated cost of one DOT visit on average (assuming five
per week, and using the Medical care component of the
CPI) would be approximately $24 in 2004 dollars [53],
higher than the $19 we assumed per visit. However, we
assumed a fixed fraction of patients on DOT, and did not
need to adjust the expected costs of tuberculosis for the
cost-saving features of the use of DOT [51,54].
Base case scenario, and uncertainty and sensitivity 
analyses
Selected parameters for our base case scenario are given in
Table 2; a complete discussion is given in the Appendix
[see Additional file 1]. We chose plausible ranges for
uncertain parameters in the model, repeating analyses
with values chosen from a uniform distribution within
the ranges, and conducted univariate sensitivity analyses.
Results
Base case scenario
For our base case scenario, we found that domestic B-noti-
fication follow-up consisting of evaluation and case treat-
ment is highly cost effective. Including therapy for LTBI as
well as treatment of active cases, we found that the pro-
gram yielded 8 net QALYs, yielded $25 000 in net savings,
and prevented 4 cases of TB. We determined the number
of quality-adjusted life-years saved, the net cost, the
number of cases prevented, and the number of deaths
averted during 20 years as a result of treating only active
cases (class TB3), as well as offering LTBI treatment for
Table 1: Program Cost Data. Program cost data derived from Medi-Cal reimbursements or other sources (column 1). All costs given 
in U.S. dollars, adjusted to year 2004 using the Medical Care component of the U.S. Consumer Price Index (U.S. Bureau of Labor 
Statistics). Note 1: For each procedure for which Medicare charges were computed, we obtained charges for all nine regions in 
California for which Medicare calculates a geographic price adjustment factor. We then computed a weighted average based on the 
year 2004 tuberculosis case count for the nine regions. Note 2: Year 2003 Medicare Part B average national allowed charges (BESS) 
Note 3: Assuming a standard regimen of isoniazid, pyrazinamide, rifampin and ethambutol for two months, followed by isoniazid and 
rifampin for four months, assuming a 65 kg adult. Note 4: weighted average of the average daily hospitalization cost for Los Angeles, 
San Diego, San Francisco [58,59], converted to 2004 dollars; weights derived from cases reported in 1995 [60] (during the CDC Cost 
of Hospitalization Study). Note 5: Inflated to 2004 dollars by the medical Consumer Price Index. Note 6: These items inflated using the 
all-items Consumer Price Index.
Variable Cost Source
New patient doctor visit 111.50 Medicare, 2004, Note 1
Established patient visit 61.25 Medicare, 2004, Note 1
Tuberculin skin test 11.78 Medicare, 2004, Note 1
Initial chest X-ray 39.68 Medicare, 2004, Note 1
Sputum collection 17.80 Medicare, 2004, Note 1
Specimen concentration 9.33 Medicare Part B, Note 2
AFB smear 7.50 Medicare Part B, Note 2
Sputum culture 14.42 Medicare Part B, Note 2
Sensitivity testing 7.38 Medicare Part B, Note 2
Mycobacterial identification 15.29 Medicare Part B, Note 2
Isoniazid, 100 tablets 8.90 Medicaid Federal Upper Limit price
Chemotherapy for active TB 1118 Drug prices Red Book, 2004; ATS recommendations; Note 3
Nurse assessment, 1/4 hr 8.40 Medi-Cal
Liver function tests 11.42 Medicare Part B, Note 2
TB hospitalization episode 25 834 Note 4; based on CDC unpublished data
Hepatitis hospital stay 10 662 Note 5; [61]
Complete blood count 9.04 Medicare Part B, Note 2
Renal function panel 12.13 Medicare Part B, Note 2
Directly observed therapy (DOT) 19.23 Medi-Cal
Disease control investigation 387.02 [51,52]; Appendix
Letter mailed 10.80 [42]; Note 6
Phone call (community worker) 13.24 [42]; Note 6
Home visit (community worker) 39.57 [42]; Note 6BMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
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individuals in ATS class TB4 and ATS class TB2. Summary
results from our base case scenario are shown in the first
line of Table 6. The active case finding component was
estimated to have prevented approximately 0.5 new cases
of TB; the treatment of individuals in class TB4 to have
prevented approximately 3.1 new cases, and finally the
treatment of individuals in class TB2 to have prevented
approximately 0.6 new cases. In this scenario, the costs of
the evaluation are offset by the potential savings due to
earlier case finding and prevention of disease by the use of
LTBI therapy. Because the evaluation costs were attributed
to the active case finding component of the program, the
treatment of TB4s was in fact cost saving, while the treat-
ment of TB2s remained highly cost effective (yielding
QALYs at a rate of approximately $4 400 per QALY, and
preventing cases at a cost of $4 700 per case prevented as
well).
Sensitivity analysis
In Tables 3, 4, 5, we vary three program performance
parameters: the evaluation rate, the starting rate, and the
completion rate, keeping all other parameters the same as
in the base-case scenario (we assume, however, no tar-
geted use of directly observed preventive therapy is
needed, and assume outreach costs for evaluation are lim-
ited to the cost of sending letters). The tables show the
costs and benefits for programs of different performance,
assuming the same variable cost structure. In Table 3, we
present the number of QALYs saved, net costs, cases
averted, and deaths with TB averted that are attributable to
the active case finding component. In Table 4, we show
the results attributable to treatment of individuals in ATS
class TB4, and in Table 5, that attributable to treatment of
individuals in ATS class TB2 (i.e., incremental results for
the decision to treat individuals in class TB4 and class TB2,
Table 2: Base case scenario parameters. Selected parameters for cost-effectiveness of California tuberculosis B-notifications. Full 
details and additional parameters are given in the Appendix [see Additional file 1]. Note 1: California TB surveillance for individuals 
from major countries of origin, 2002. Note 2: one minus the relative risk of disease given completion of LTBI therapy relative to no 
therapy, assuming isoniazid-sensitive infection. Note 3: assuming no false positives due to prior BCG vaccination. Note 4: rate per 100 
000 person-years. See Appendix [Additional file 1] for further details and complete references.
Description Values
Mean age (Note 1) 53.3
INH resistance 0.129
Drug-induced hepatitis rates 0.0008 to 0.0028
Efficacy of completed regimen (Note 2) 70%
Mean time to passive diagnosis 74 days
TST sensitivity 93%
TST specificity (Note 3) 99%
Probability of fast progression to TB after infection 0.05
Probability of finding a TB contact 80%
Fraction of individuals with B-notification
with active disease 3%
in class TB4 60%
in class TB2 22%
Fraction of
baseline active cases smear positive 7.5%
TB4s eligible for LTBI therapy 63%
Hospitalization probability
actively detected smear-positive 0.35
actively detected smear-negative 0.081
passively detected smear-positive 0.66
passively detected smear-negative 0.51
Transmission (new infections per year)
smear-positive source case 8
smear-negative source case 0.8
Attrition cascade for domestic follow-up after B-notification
Evaluation rate 60%
Starting rate, LTBI therapy 80%
Completion rate, LTBI therapy 75%
Reactivation rate at baseline, Note 4
class TB4 600
class TB2 217BMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
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respectively). The upper and middle values of the evalua-
tion rates, starting rates, and completion rates were based
on unpublished data from selected California local health
jurisdictions.
In Table 6, we present the results of univariate sensitivity
analysis. Line One of the table shows results from the base
case scenario; we show the cost-effectiveness of evaluation
and treating active cases only, the incremental cost-effec-
Table 4: Program performance. The incremental cost-effectiveness of evaluation and treatment of disease among a hypothetical 
cohort of 1000 B-notification patients followed for 20 years. The table presents the outcomes of a decision to treat individuals in ATS 
class TB4, listing the number of QALYs averted, the net cost, the number of cases averted, and the difference in the number of deaths 
among individuals with tuberculosis with and without the program, for various levels of the evaluation rate, the starting rate, and the 
completion rate. All outcomes are discounted at a rate of three percent per year. Each row is computed by averaging 10 000 
replications of a cohort of 1 000 individuals each, over a 20-year period; standard errors are given in parentheses.
Evaluation Rate Starting Rate Completion Rate QALYs Saved Net costs (1000s) Cases Averted TB Deaths Averted
45% 35% 30% 1.1 (0.1) -3.2 (1) 0.79 (0.06) 0.039 (0.005)
45% 35% 55% 0.63 (0.2) -2.4 (0.7) 0.95 (0.05) 0.018 (0.008)
45% 35% 75% 0.79 (0.1) -1.9 (0.9) 1 (0.05) 0.032 (0.007)
45% 45% 30% 0.85 (0.2) -3.6 (0.7) 0.97 (0.04) 0.028 (0.009)
45% 45% 55% 1.3 (0.3) -3.8 (0.9) 1.1 (0.05) 0.048 (0.01)
45% 45% 75% 1.4 (0.2) -4.5 (0.8) 1.4 (0.05) 0.058 (0.01)
45% 80% 30% 1.8 (0.1) -6.6 (1) 1.7 (0.05) 0.07 (0.006)
45% 80% 55% 2.5 (0.2) -6.7 (1) 2.1 (0.04) 0.088 (0.009)
45% 80% 75% 2.4 (0.2) -6.9 (1) 2.4 (0.06) 0.09 (0.01)
65% 35% 30% 1.3 (0.2) -5.2 (1) 1.2 (0.04) 0.049 (0.009)
65% 35% 55% 1.7 (0.2) -3.4 (1) 1.3 (0.05) 0.065 (0.009)
65% 35% 75% 1.4 (0.1) -3.3 (0.7) 1.5 (0.03) 0.048 (0.009)
65% 45% 30% 1 (0.2) -6.1 (2) 1.4 (0.08) 0.04 (0.007)
65% 45% 55% 2.1 (0.2) -6.1 (0.7) 1.8 (0.04) 0.077 (0.01)
65% 45% 75% 2.2 (0.2) -5.5 (0.9) 1.9 (0.03) 0.086 (0.009)
65% 80% 30% 2.5 (0.2) -11 (2) 2.6 (0.07) 0.095 (0.008)
65% 80% 55% 3 (0.2) -10 (0.8) 3 (0.04) 0.11 (0.01)
65% 80% 75% 3.5 (0.1) -8.3 (0.6) 3.4 (0.03) 0.13 (0.007)
85% 35% 30% 1.7 (0.2) -5.6 (1) 1.4 (0.06) 0.065 (0.007)
85% 35% 55% 2.2 (0.2) -7.4 (1) 1.8 (0.04) 0.089 (0.008)
85% 35% 75% 2.2 (0.3) -5.6 (0.7) 1.9 (0.04) 0.087 (0.01)
85% 45% 30% 2 (0.2) -8.1 (0.9) 1.9 (0.04) 0.074 (0.01)
85% 45% 55% 2.3 (0.2) -8 (1) 2.4 (0.04) 0.091 (0.008)
85% 45% 75% 2.5 (0.2) -6.6 (0.8) 2.6 (0.04) 0.093 (0.01)
85% 80% 30% 3.7 (0.2) -14 (1) 3.4 (0.05) 0.14 (0.01)
85% 80% 55% 4.1 (0.1) -13 (0.7) 3.9 (0.03) 0.15 (0.009)
85% 80% 75% 4.5 (0.2) -12 (0.9) 4.4 (0.04) 0.16 (0.008)
Table 3: Program performance. The incremental cost-effectiveness of evaluation and treatment of disease among a hypothetical 
cohort of 1 000 B-notification patients followed for 20 years. This table presents the outcomes for the active case finding component of 
the program, and lists the number of QALYs averted, the net cost, the number of cases averted, and the difference in the number of 
deaths among individuals with tuberculosis with and without active case finding, for three levels of the evaluation rate. All outcomes 
are discounted at a rate of three percent per year. Each row is computed by averaging 10 000 replications of a cohort of 1 000 
individuals each, over a 20-year period; standard errors are given in parentheses.
Evaluation Rate Starting Rate Completion Rate QALYs Saved Net costs (1000s) Cases Averted TB Deaths 
Averted
45% - - 1.9 (0.09) -11 (0.5) 0.18 (0.02) 0.059 (0.003)
65% - - 2.9 (0.08) -16 (0.5) 0.26 (0.02) 0.089 (0.004)
85% - - 3.9 (0.08) -22 (0.5) 0.38 (0.02) 0.12 (0.003)BMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
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tiveness of treating TB4s, and finally the overall cost-effec-
tiveness of evaluation and therapy for active cases,
individuals in class TB4, and individuals in class TB2.
Assuming a mean passive treatment delay of 100 days, or
a screening delay of two weeks on average following entry
into the U.S., had little effect (note that this result depends
on an assumption that few smear-negative individuals
will become smear positive during this short time).
Assuming six percent of the population are active TB cases
(instead of three percent) results in far greater health ben-
efits (cases prevented, deaths averted, QALYs saved) and
far greater cost savings; in our base case, the evaluation
costs were almost exactly offset by savings due to treat-
ment and interrupting transmission, and when there are
more cases to be found, the cost savings considerably
exceed the evaluation costs. Increasing the number of new
infections per year that a case can cause to 16 per year for
a smear-positive case resulted in more QALYs saved and in
cost savings (line 5). We varied the four hospitalization
rates as shown in the Table; higher hospitalization rates
for actively found cases and lower hospitalization rates for
passively found cases all resulted (as expected) in
increased net costs. In the least cost-effective of these sce-
narios, the overall cost-effectiveness ratio was still approx-
imately $20 000 per QALY saved, well below the
commonly-cited willingness-to-pay threshold of $50 000
per QALY (and the cost per case prevented was approxi-
mately $35 000). We also found that a 20 percent increase
in all costs other than tuberculosis hospitalization costs
essentially eliminated the predicted overall net cost-sav-
ings without changing the finding that the domestic B-
notification follow-up is cost-effective. On the other
hand, a 20 percent increase in hospitalization costs
renders each program component cost-saving on average,
since each prevented case saves more money. When we
assumed that the reactivation rates for individuals in class
TB4 were 430 per 100 000 person-years (instead of 600
per 100 000), the treatment of TB4s became approxi-
mately cost-neutral, but still saved QALYs and prevented
Table 5: Program performance. The incremental cost-effectiveness of evaluation and treatment of disease among a hypothetical 
cohort of 1000 B-notification patients followed for 20 years. The table presents the outcomes of a decision to treat individuals in ATS 
class TB2, listing the number of QALYs averted, the net cost, the number of cases averted, and the difference in the number of deaths 
among individuals with tuberculosis with and without the program, for various levels of the evaluation rate, the starting rate, and the 
completion rate. All outcomes are discounted at a rate of three percent per year. Each row is computed by averaging 10 000 
replications of a cohort of 1 000 individuals each, over a 20-year period; standard errors are given in parentheses.
Evaluation Rate Starting Rate Completion Rate QALYs saved Net costs (1000s) Cases Averted TB Deaths Averted
45% 35% 30% 0.12 (0.08) 0.022 (0.4) 0.2 (0.02) 0.0073 (0.005)
45% 35% 55% 0.22 (0.1) 0.43 (0.4) 0.2 (0.02) 0.011 (0.006)
45% 35% 75% 0.25 (0.07) 0.09 (0.5) 0.23 (0.02) 0.013 (0.004)
45% 45% 30% 0.17 (0.08) 0.34 (0.2) 0.2 (0.02) 0.013 (0.004)
45% 45% 55% 0.32 (0.06) 0.86 (0.4) 0.24 (0.02) 0.016 (0.002)
45% 45% 75% 0.23 (0.06) 1.1 (0.6) 0.28 (0.02) 0.011 (0.003)
45% 80% 30% 0.35 (0.1) 1.4 (0.5) 0.33 (0.02) 0.014 (0.006)
45% 80% 55% 0.42 (0.1) 2.3 (0.5) 0.4 (0.02) 0.018 (0.005)
45% 80% 75% 0.55 (0.06) 2.4 (0.4) 0.45 (0.02) 0.025 (0.004)
65% 35% 30% 0.21 (0.07) 0.24 (0.4) 0.21 (0.02) 0.01 (0.003)
65% 35% 55% 0.1 (0.07) 1.3 (0.4) 0.25 (0.02) 0.0025 (0.004)
65% 35% 75% 0.28 (0.07) 1.9 (0.2) 0.29 (0.01) 0.016 (0.004)
65% 45% 30% 0.26 (0.08) 1.1 (0.4) 0.27 (0.01) 0.01 (0.005)
65% 45% 55% 0.44 (0.07) 0.87 (0.4) 0.36 (0.03) 0.019 (0.003)
65% 45% 75% 0.62 (0.06) 1.7 (0.4) 0.42 (0.02) 0.026 (0.004)
65% 80% 30% 0.51 (0.04) 1.6 (0.3) 0.49 (0.01) 0.024 (0.003)
65% 80% 55% 0.72 (0.09) 1.9 (0.5) 0.64 (0.03) 0.035 (0.004)
65% 80% 75% 0.64 (0.07) 3.7 (0.3) 0.69 (0.03) 0.028 (0.003)
85% 35% 30% 0.34 (0.08) 1 (0.4) 0.3 (0.02) 0.015 (0.004)
85% 35% 55% 0.34 (0.1) 1.4 (0.5) 0.32 (0.02) 0.014 (0.004)
85% 35% 75% 0.29 (0.07) 2.4 (0.5) 0.37 (0.02) 0.013 (0.004)
85% 45% 30% 0.37 (0.07) 1 (0.5) 0.36 (0.02) 0.016 (0.004)
85% 45% 55% 0.36 (0.05) 2.4 (0.6) 0.43 (0.02) 0.015 (0.003)
85% 45% 75% 0.49 (0.08) 3 (0.6) 0.46 (0.03) 0.022 (0.005)
85% 80% 30% 0.59 (0.07) 2 (0.3) 0.66 (0.02) 0.026 (0.002)
85% 80% 55% 0.77 (0.09) 3.9 (0.5) 0.79 (0.02) 0.034 (0.003)
85% 80% 75% 0.85 (0.06) 5.3 (0.4) 0.85 (0.02) 0.036 (0.003)BMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
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cases. Similarly, we examined the cost-effectiveness of
treating individuals classified as TB2 in their evaluation
(not shown in Table 6). In the base case scenario, the reac-
tivation rate was 217 per 100 000 person years [38-40]
(see Appendix [Additional file 1] for details), and the
treatment of individuals identified as TB2 was still cost-
effective as discussed earlier. With an incidence rate of 100
per 100 000 person-years, however, the expected gain in
QALYs was only 0.3, the cost-effectiveness ratio is approx-
imately $27 000 per QALY, and the net cost to prevent one
case is approximately $30 000.
Because of the potential importance of INH-induced hep-
atitis, we also examined the consequences of assuming
that the levels of hepatitis risk were higher than we
assumed for the base case. We considered the case of treat-
ing individuals in ATS class 2, who were at the lowest risk
for tuberculosis progression. We found that when the base
case rates were multiplied by a factor of approximately
eighteen or more, preventive therapy led to a net loss of
QALYs; preventive therapy yields QALYs at a cost of less
than $50 000 per QALY provided the hepatitis rates are no
greater than approximately fifteen times the values we
assumed in the base case. Although all deaths due to INH-
related hepatitis are, in principle, attributable to the inter-
vention, while not all deaths with tuberculosis can be
assumed to be attributable to tuberculosis, the results of
this sensitivity analysis would appear to support the
Table 6: Sensitivity analysis. Univariate sensitivity analysis of base case scenario (based on 10 000 replications per line). All QALYs and 
costs are discounted at three percent per year (unless indicated otherwise). Line One gives results for the base case scenario; in each 
other line, one parameter is varied from the Base Case value (column 2) to a new value (column 3). All costs are given in $1 000 2004 
U.S. dollars. Negative costs represent savings. Standard errors are given in parentheses. Note 1: new infections per year caused by a 
smear positive case. Note 2: rate per 100 000 person-years.
Parameter varied Value Active cases Add TB4s Overall (all)
Base New QALYs Cost QALYs Cost QALYs Cost
None - - 4.1 (0.3) -17 (1.6) 2.9 (0.1) -10 (0.7) 7.7 (0.3) -25 (1.5)
Passive treatment delay (days) 74 100 5.8 (0.2) -14 (1.4) 3.7 (0.2) -12 (1) 10 (0.3) -22 (1.7)
Screening delay (days) 0 14 4.4 (0.3) -17 (1.4) 3.2 (0.2) -11 (1.1) 8.1 (0.2) -25 (1.7)
Fraction of active cases 3% 6% 8.1 (0.3) -290 (2.2) 3.1 (0.2) -11 (0.7) 12 (0.4) -290 (2.5)
Baseline smear-positive rate 7.5% 15% 5.2 (0.3) -9.6 (0.9) 3.3 (0.3) -11 (0.8) 9.3 (0.4) -18 (0.9)
Transmission rate (Note 1) 8 16 4.2 (0.3) -22 (1.6) 3.4 (0.2) -12 (1) 8.3 (0.3) -33 (1.6)
Hospitalization rates
Actively detect, smear pos. 0.35 0.66 4.1 (0.2) 0.8 (1) 3.6 (0.2) -11 (1) 8.3 (0.3) -7.2 (1.6)
Passively detect, smear pos. 0.66 0.33 3.8 (0.13) +8.3 (1.7) 3.4 (0.2) -1.0 (0.7) +7.9 (0.3) +12 (2.3)
Actively detect, smear neg. 0.081 0.162 4.1 (0.2) +27 (0.7) 3 (0.18) -8.6 (0.6) 7.7 (0.3) +22 (1.2)
Passively detect, smear neg. 0.51 0.255 3.5 (0.3) +140 (0.6) 3.2 (0.15) 1.5 (0.8) 7.3 (0.3) +150 (1)
Reactivation rates, Note 2
TB4s 600 430 4 (0.3) -16 (1.3) 2.5 (0.15) 1.0 (0.7) 7.1 (0.3) -12 (2)
Cost multipliers
Hospitalization costs same +20% 4.1 (0.3) -67 (1.5) 3 (0.13) -16 (0.9) 7.8 (0.3) -83 (1.5)
Costs, excluding hospital same +20% 3.4 (0.18) +14 (0.9) 3.5 (0.2) -4.6 (1.1) 7.7 (0.3) +14 (1.6)
Selected costs
Nurse refill visit 16.80 8.40 3.7 (0.2) -17 (1.1) 3.3 (0.13) -26 (0.8) 7.5 (0.3) -43 (1.4)
DOT visit 19.23 25.00 4.5 (0.2) -16 (1.2) 3.0 (0.2) -11 (1) 7.8 (0.4) -24 (1.8)
TST specificity 0.99 0.875 4.1 (0.2) -14 (1.1) 3.0 (0.2) -11 (0.9) 7.6 (0.3) -21 (1.2)
Fraction INH resistant 0.13 0.2 3.9 (0.3) -14 (1) 2.3 (0.2) -5.3 (0.8) 6.7 (0.4) -16 (0.9)
Risk multiplier, severe hepatitis 1 3 3.9 (0.3) -16 (0.9) 3.0 (0.15) -5.4 (0.5) 7.6 (0.3) -17 (1)
Selected disutilities
Hepatitis hospitalization 0.4 0.9 4.3 (0.3) -15 (1.5) 3.1 (0.2) -10 (0.9) 8.0 (0.3) -23 (1.6)
Outpatient hepatitis 0.265 0.5 4.3 (0.2) -16 (1.3) 3.1 (0.17) -9.9 (1.1) 8.0 (0.3) -24 (2)
Other INH side-effects 0.1 0.2 3.9 (0.2) -15 (1) 2.9 (0.13) -10 (0.7) 7.4 (0.2) -22 (1.2)
Untreated TB 0.1 0.2 4.8 (0.19) -15 (1) 3.6 (0.15) -10 (0.9) 9.0 (0.3) -22 (1.5)
Lost QALYs, INH one month 0 0.01 4.5 (0.3) -15 (1.1) -15 (0.2) -9.9 (0.8) -16 (0.4) -22 (0.9)
Disutility multipliers
TB hospitalization 1 0.5 4.0 (0.19) -16 (1.4) 3.3 (0.1) -10 (1) 7.9 (0.2) -24 (1.3)
Outpatient TB 1 0.5 4.2 (0.3) -16 (1.3) 3.4 (0.2) -8 (0.7) 8.3 (0.3) -21 (1.6)
Discount rate per year 0.03 0.05 3.2 (0.15) -13 (1) 2.4 (0.13) -6.9 (1.2) 5.9 (0.2) -16 (1.6)
TST sensitivity 0.93 0.95 4.2 (0.2) -17 (1.3) 3.4 (0.15) -11 (1) 8.3 (0.3) -25 (1.7)
TST specificity 0.99 0.95BMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
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robustness of findings that the benefits of tuberculosis
prevention, on the whole, outweigh the adverse outcomes
due to isoniazid. Because of the importance of the fraction
of individuals screened who have active disease, we per-
formed a threshold analysis for this parameter by repeat-
ing the base case, but varying only the fraction with active
disease (and fitting a linear model to the simulation
results). These findings suggest that the intervention
becomes net cost saving when the fraction of active cases
is approximately 2.7 percent or greater, but that the inter-
vention remains cost-effective at the willingness-to-pay
threshold of $50 000 provided the active case fraction is
greater than 0.4 percent (0.004). The estimated cost-effec-
tiveness ratio for various levels of the active case fraction
are provided in Table 8.
We also examined different values of the proportion of
individuals in ATS class TB4 and in ATS class TB2. Barring
special circumstances, individuals in ATS class TB2 should
not receive a tuberculosis B-notification under current
policies, since such individuals have normal chest X-rays,
but as discussed above, a fraction of tuberculosis B-notifi-
cations nonetheless have been found to be in ATS class 2.
In Table 7, we assumed that the fraction of active cases was
either 1.5% or 3%, that the fraction of individuals in ATS
class TB4 varied from 30% to 75%, and that the fraction
of individuals in ATS class TB2 who were not in ATS
classes 3 or 4 varied from 15% to45% (providing the total
fraction was less than 1.0, as shown). We present the aver-
age net cost and QALYs saved by evaluation and treatment
of TB3s, and then the further incremental net cost and
incremental number of QALYs saved by treatment of TB2s
and TB4s, and finally the aggregate net cost and number
of QALYs saved by evaluation and treatment of active
cases, TB2s, and TB4s (last two columns). In this table, we
averaged the results of 1000 random simulations and
present mean values only (omitting the standard errors
for the sake of brevity). Table 7 shows that for a given
active case fraction, an increasing fraction of individuals
in ATS class TB4 corresponds both to increased costs
(owing to the greater evaluation costs of individuals with
abnormal chest X-ray) and to increased opportunity for
prevention of TB. The least cost-effective scenario we
examined had 1.5% active cases, but 75% TB4s; the cost
per QALY saved was approximately $21 000, and the cost
per case prevented was approximately $29 000.
Resource allocation
What do these results imply for improvement of public
health performance based on cost-effectiveness? We used
our model to compare the cost-effectiveness of improve-
ment of evaluation rates with offering LTBI therapy to
individuals of class TB2 or TB4, and with efforts to
improve starting or completion rates among those popu-
lations offered LTBI therapy. We applied the data from a
study of efforts to improve B-notification evaluation rates
in Santa Clara County, California [42] using letters,
phone calls, and home visits.
Table 7: Fraction latently infected. Bivariate sensitivity analysis of base case scenario, varying the percentage of individuals in ATS 
classes TB3 (active cases), TB4, and TB2. The results reported are the average values for 1 000 replications, with standard errors given 
in parentheses. All QALYs and costs are discounted at three percent per year; costs are listed in thousands of 2004 U.S. dollars, and 
negative costs represent savings. All parameters are the same as in the base case scenario unless otherwise indicated; the results 
shown assume that treatment will be undertaken on individuals in ATS class TB2 and TB4 whenever possible.
Percent Active TB Percent TB4 Percent TB2 QALYs saved Net cost Cases averted
1.5 30 15 4.3 (0.2) 66 (1.1) 2.3 (0.05)
1.5 30 30 4.4 (0.3) 67 (1.5) 2.7 (0.07)
1.5 30 45 5.4 (0.3) 72 (1.2) 3.0 (0.07)
1.5 45 15 5.0 (0.4) 88 (1.3) 3.0 (0.09)
1.5 45 30 5.2 (0.4) 90 (1.2) 3.4 (0.07)
1.5 45 45 6.0 (0.2) 94 (0.9) 3.9 (0.06)
1.5 60 15 5.7 (0.4) 110 (1.1) 3.8 (0.07)
1.5 60 30 6.2 (0.3) 120 (1.6) 4.0 (0.07)
1.5 75 15 6.4 (0.3) 130 (1.9) 4.5 (0.11)
3.0 30 15 6.2 (0.2) -67 (1.2) 2.5 (0.06)
3.0 30 30 6.4 (0.3) -64 (1.4) 2.8 (0.06)
3.0 30 45 7.0 (0.2) -64 (1.2) 3.3 (0.05)
3.0 45 15 6.8 (0.3) -46 (1.9) 3.1 (0.06)
3.0 45 30 7.2 (0.4) -42 (1.4) 3.6 (0.11)
3.0 45 45 7.5 (0.4) -40 (1.1) 4.0 (0.07)
3.0 60 15 7.4 (0.3) -25 (2) 4.0 (0.15)
3.0 60 30 8.5 (0.3) -21 (1.8) 4.5 (0.1)
3.0 75 15 9.1 (0.3) -1.4 (1.6) 4.8 (0.07)BMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
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Our results are shown in Table 9. Beginning with a purely
passive program which only treated active cases without
actively seeking them, we found that the highest first pri-
ority was a low-cost measure to improve evaluation rates
(sending letters), which yielded approximately 3 QALYs
and a net savings of approximately $10 000. Once this
was implemented, the best step was to begin treating indi-
viduals identified as in class TB4, yielding approximately
3 QALYs at a net savings of $11 000; treating TB4s accom-
plishes more once the improvements in evaluation are in
place. The next step is to improve starting rates of LTBI
therapy for TB4s now that it has been decided to offer
therapy. After this, treatment of TB2s is the next best step.
Finally, further improvements in evaluation up to home
visits continue to add a small additional benefit. Directly
observed preventive therapy, however, does not appear
cost-effective (yielding QALYs at a cost of in excess of
$100 000) in this population (we have assumed that there
is no HIV infection in this population, and we have not
modeled any other risk factors for progression). The rank-
ings in Table 9 are somewhat sensitive to the assumed out-
reach efficiencies, fraction of active cases and TB4s, and
other parameters and may thus vary somewhat from place
to place. However, improvement in evaluation rates, low
cost efforts to improve starting rates, and offering therapy
to individuals (both TB2 and TB4) identified through
domestic B-notification remain highly cost-effective to
cost-saving for a wide range of parameter values.
Overall benefits
What are the benefits from domestic B-notification fol-
low-up to California as a whole? With approximately 3
700 B-notifications for California in 2002, the scenarios
in Tables 3, 4, 5 suggest that domestic follow-up for one
year would prevent approximately 6–26 cases per year
over time (see Appendix [Additional file 1] for details),
with slight estimated annual savings of approximately
$67 000–$170 000 (though these values are highly sensi-
tive to changes in the fraction of active cases found and
the hospitalization costs).
Discussion
We found that evaluation and treatment of active cases for
new immigrants with tuberculosis B-notifications is
highly cost-effective, yielding quality-adjusted life years at
approximate cost neutrality. We assumed, however, that
actively detected cases are substantially less likely to be
hospitalized than passively detected cases [16]. We also
found that offering LTBI therapy for individuals identified
as having LTBI through their domestic B-notification eval-
uation is highly cost-effective as well, and is in fact cost
saving on average for individuals in class TB4. We found
that, provided monitoring maintains relatively low levels
of INH-related hepatitis [20], the benefits of LTBI therapy
outweigh the potential harm due to hepatitis (as other
studies have found). Our results also suggest that program
performance may be improved in a cost-effective manner,
and that the highest priorities should be LTBI therapy for
individuals in ATS class TB4 and improvement of evalua-
tion rates. Importantly, treatment of individuals in class
TB2 was still cost-effective, though our results suggest that
routine use of directly-observed therapy for LTBI cases
(with no othermedical risk factors) may fall short of com-
mon willingness-to-pay thresholds. It is important, how-
ever, to realize that this conclusion applies only to
domestic B-notification patients at low risk of HIV infec-
tion, and that we assumed no other risk factors for tuber-
culosis progression. For populations with HIV or other
risk factors for progression, directly observed preventive
therapy may be cost-effective [13].
However, despite the cost-effectiveness of domestic B-
notification follow-up, we cannot expect such follow-up
to decrease the number of overall California TB cases by
more than approximately one percent. While our cost-
effectiveness arguments imply that domestic B-notifica-
tion is valuable, it simply reaches too few people to have
Table 8: Cost-effectiveness. Estimated cost-effectiveness ratio as the fraction of active cases vary, with all parameters otherwise equal 
to the base case scenario. All QALYs and costs are discounted at three percent per year; costs are listed in 2004 U.S. dollars. The cost-
effectiveness ratios are based on the assumption that all active cases and latently infected individuals (ATS class 2 and class 4) are 
eligible for treatment.
Fraction of active cases 40% TB4s 60% TB4s
Cost per QALY saved Cost per case averted Cost per QALY saved Cost per case averted
0% $72 000 $72 000 $64 000 $66 000
0.5% $47 000 $57 000 $45 000 $53 000
1.0% $30 000 $41 000 $31 000 $41 000
1.5% $17 000 $27 000 $19 000 $29 000
2.0% $7 000 $12 000 $10 000 $17 000
2.5% cost saving cost saving $3000 $5 000
3.0% cost saving cost saving cost saving cost savingBMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
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a large effect on the overall case rate. Other measures, such
as enhanced screening and evaluation of other foreign-
born populations (such as undocumented residents or
individuals on short-term visas) or extending the overseas
screening to attempt toidentify individuals with LTBI [2],
would be needed to cause a larger effect on the total
number of cases.
Several limitations apply to our findings. Our findings
were derived from a transmission model of TB transmis-
sion, case-detection, and reactivation; we attempted to
make conservative assumptions and to use a wide range
for many parameters. For many of the costs of the model,
accurate estimates are not available; we utilized Medicare
reimbursement rates wherever possible, and constructed a
highly conservative cost accounting for tuberculosis med-
ical costs; we nevertheless found that domestic follow-up
was cost-saving or highly cost-effective – the true cost sav-
ings may be higher than we found. We also used expected
years of life in the absence of available estimates of qual-
ity-adjusted life expectancy, and we attributed all deaths
of TB patients to tuberculosis itself. Sensitivity analysis,
however, suggests that these assumptions do not change
our conclusion that domestic B-notification follow-up is
cost-effective under widely accepted willingness-to-pay
standards (e.g. $50 000 per QALY gained). Furthermore,
note that our model did not include lost productivity,
which would have improved the cost-effectiveness of the
interventions examined. Also, because individuals with
HIV infection are generally barred from immigration, our
model did not address the cost-effectiveness of TB preven-
tion among the HIV-infected. Also, we did not address
whether individuals beyond a certain age should or
should not receive LTBI therapy; our results only demon-
strate net cost-effectiveness aggregating over age groups.
Uncertainty in the benefits of active case finding plays a
major role in shaping the variability in our findings, and
more information would be needed to precisely character-
ize the medical and fiscal benefits of B-notification fol-
low-up. Finally, parameter estimation uncertainty
(especially for the fraction of active cases among those
screened, the progression rate from smear-negative to
smear-positive, hospitalization costs (for actively and pas-
sively diagnosed cases) and the rate of reactivation of
LTBI) limits theprecision of our results. It is also impor-
tant to note that decisions based on aggregating QALYs
across individuals may not yield results in agreement with
the expressed social preferences of most people, a finding
Table 9: Program priorities. Program priorities determined by decision analysis of the base case scenario, based on considering (1) 
improvement of evaluation rates by letters, phone calls, and home visits, (2) offering LTBI therapy to individuals in class TB2 or class 
TB4, (3) improving rates of starting LTBI therapy to those it is offered to (by education and outreach), and (4) improvement of rates 
of completion of LTBI therapy to those it is offered to (by targeted DOPT). Beginning with a minimal program (line 1), the available 
options (column two) were compared. Options that produced net health benefits and cost savings were always preferred over options 
that produced net health benefits at a net total cost; whenever more than one option produced health benefits and cost savings, we 
chose the option yielding the greatest savings (other choices of decision rule are possible). Options yielding health benefits at net cost 
were to be ranked according to the cost-effectiveness ratio. The resulting program actions are given in the left hand column of the 
following row, which forms the basis for the next comparison; notice that the costs and benefits of a given course of action (such as 
starting TB4s on LTBI therapy) depend on previous choices (such as whether or not we have sent letters to improve evaluation rates, 
yielding more TB4s to treat). The parameters and assumptions of the base case are discussed in the text and Appendix [Additional file 
1].
Beginning with ... Choose between ... Best choice
1. Treat only active cases; detect them only 
passively
(1) Offer LTBI treatment to TB2s or TB4s, or
(2) send letters to improve evalua tion
Send letters (2.7 QALYs gained, 
$10 000 in net sav ings)
2. Send letters; treat active cases (1) Offer LTBI treatment to TB2s,
(2) Offer LTBI treatment to TB4s, or
(3) make phone calls to improve evaluation rates
Treat TB4s (3.2 QALYs gained, 
$11 000 in net savings)
3. Treat active cases and TB4s; improve 
evaluation by letters
(1) Offer LTBI treatment to TB2s,
(2) make phone calls to improve evaluation rates 
further,
(3) improve rates of starting ther apy for TB4s, or
(4) improve completion rates by DOPT
Improve starting rates (1.3 QALYs 
saved, $1 800 in net savings)
4. Treat active cases and TB4s; improve 
evaluation rates by letters; improve starting 
rates
(1) send letters to improve evalua tion rates further,
(2) treat TB2s, or
(3) improve completion rates by DOPT
Treat TB2s (0.7 QALYs saved, $3 
000 in net cost)
5. Treat active cases, TB2s, and TB4s; improve 
evaluation by letters; improve rates of starting 
therapy
(1) Further improve evaluation rates by phone calls, or
(2) improve rates of completing therapy (by targeted 
DOPT)
Phone calls (0.5 QALYs saved, 
approximately $1 000 in net 
savings)
6. Treat active cases, TB4s, and TB2s; improve 
evaluation by letters and phone calls
(1) Further improve evaluation rates by home visits, or
(2) improve rates of completing therapy by using 
targeted DOPT
Home visits (0.3 QALYs saved, 
approximately $1 000 in net cost)
7. Treat active cases, TB4s, and TB2s; improve 
evaluation by letters and phone calls
(1) improve rates of completing therapy by using 
targeted DOPT
> $100 000 per QALY saved; no 
further interventionBMC Public Health 2006, 6:157 http://www.biomedcentral.com/1471-2458/6/157
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which, in particular, may occur when small increments of
QALYs aggregated across many people outweigh large
increments in QALYs for a few, e.g. [55,56]. This circum-
stance arises in our model when small decrements in util-
ity due to INH pill-taking for all individuals undergoing
preventive therapy may accumulate to outweigh the
tuberculosis deaths prevented (as seen in Table 6). How-
ever, for the base case, the number of net QALYs saved is
largely the result of tuberculosis cases (and resulting
deaths) prevented (hepatitis, and other side effects being
relatively small contributors), and serves to allow us to
compare our proposed interventions to commonly-
accepted willingness-to-pay standards.
Our analytic perspective was chosen to provide guidance
to local health jurisdictions who may be faced with the
choice of how much to invest in domestic follow-up of
individuals already identified through tuberculosis B-
notification. This choice of analytic perspective, however,
led us to exclude the costs of the overseas screening itself,
both to the immigrant and to the U.S. (since we assume
the program as mandated and that these costs are in any
event paid), as well as any overseas benefits of the over-
seas screening itself (such as earlier detection of smear-
positive cases). Thus, our results have no bearing on the
cost-effectiveness of overseas screening as such
[11,12,14,57] or of the current U.S. screening policies in
particular, but serve rather to emphasize the value of
domestic follow-up of patients who have already been
screened – given the policy as it is currently being imple-
mented.
Conclusion
Our findings indicate that domestic B-notification follow-
up is a cost-effective intervention that is warranted under
commonly-cited willingness-to-pay thresholds; domestic
B-notification benefits the patients served as well as the
general community in a cost-effective manner. While
most of the benefits result from the active case-finding
component, it is also cost-effective to treat latent TB infec-
tion. Large changes in the case burden, however, cannot
be expected from domestic B-notification follow-up
under current conditions. Nevertheless, our conclusions
support augmented investment in the domestic follow-up
in B-notification, and suggest that the program is not only
cost-effective, but may actually be cost-saving.
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